Evidence map›Paper›PMID 28039261›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Molecular Pathways: Mucins and Drug Delivery in Cancer.

Chinthalapally V Rao, Naveena B Janakiram, Altaf Mohammed

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Mucin Glycans: A Target for Cancer Therapy.Molecules (Basel, Switzerland) · 2023
    Review
  9. Sequencing Analysis ofCurrent issues in molecular biology · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Hematology and Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. altaf-mohammed@ouhsc.edu cv-rao@ouhsc.edu.
Naveena B JanakiramCenter for Cancer Prevention and Drug Development, Hematology and Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Altaf MohammedCenter for Cancer Prevention and Drug Development, Hematology and Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. altaf-mohammed@ouhsc.edu cv-rao@ouhsc.edu.
University of Oklahoma Health Sciences Center · US

Funding

Targeting cancer stem cell initiation during pancreatic cancer developmentR03CA181584 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JANAKIRAM, NAVEENA B · 2014 to 2015
$148k
Targeting mPGES-1/5-LOX for Prevention of CRC in High-Risk VeteransI01BX003198 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI RAO, CHINTHALAPALLY V. · 2016 to 2020
–
BLRD VA I01 BX003198NCI NIH HHS HHSN261201200013INCI NIH HHS N01 CN053300NCI NIH HHS R03 CA181584
6 · The paper itself

Abstract

Over the past few decades, clinical and preclinical studies have clearly demonstrated the role of mucins in tumor development. It is well established that mucins form a barrier impeding drug access to target sites, leading to cancer chemoresistance. Recently gained knowledge regarding core enzyme synthesis has opened avenues to explore the possibility of disrupting mucin synthesis to improve drug efficacy. Cancer cells exploit aberrant mucin synthesis to efficiently mask the epithelial cells and ensure survival under hostile tumor microenvironment conditions. However, O-glycan synthesis enzyme core 2 beta 1,6 N-acetylglucosaminyltransferase (GCNT3/C2GnT-2) is overexpressed in Kras-driven mouse and human cancer, and inhibition of GCNT3 has been shown to disrupt mucin synthesis. This previously unrecognized developmental pathway might be responsible for aberrant mucin biosynthesis and chemoresistance. In this

Indexed as

AnimalsDrug Delivery SystemsHumansMiceMolecular Targeted TherapyMucinsN-AcetylglucosaminyltransferasesNeoplasmsPolysaccharidesProto-Oncogene Proteins p21(ras)Signal TransductionTumor Microenvironmentbeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3KRAS protein, humanMucinsN-AcetylglucosaminyltransferasesPolysaccharidesProto-Oncogene Proteins p21(ras)

Identifiers

PMID28039261
PMCPMC6038927
OpenAlexW2563363007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.